Artwork

内容由Clinical Care Options, LLC and Clinical Care Options提供。所有播客内容(包括剧集、图形和播客描述)均由 Clinical Care Options, LLC and Clinical Care Options 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

Evolving Role of BTK Inhibitors in CLL: Experts Answer Your Questions

10:33
 
分享
 

Manage episode 346581938 series 3256997
内容由Clinical Care Options, LLC and Clinical Care Options提供。所有播客内容(包括剧集、图形和播客描述)均由 Clinical Care Options, LLC and Clinical Care Options 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

In this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include:

  • Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registrational trial today
  • Relevance of overall response rate vs progression-free survival for BTK inhibitor therapy
  • Approval of ibrutinib/venetoclax combination therapy for patients with CLL
  • Key differences between zanubrutinib and acalabrutinib in the treatment of patients with CLL
  • How to transition/overlap next therapy in patients with CLL with progression while receiving a BTK inhibitor

Faculty:
Farrukh T. Awan, MD
Associate Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Nicole Lamanna, MD
Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Link to the complete program, including downloadable slidesets and an on-demand webcast:
https://bit.ly/3EjvSKm

  continue reading

168集单集

Artwork
icon分享
 
Manage episode 346581938 series 3256997
内容由Clinical Care Options, LLC and Clinical Care Options提供。所有播客内容(包括剧集、图形和播客描述)均由 Clinical Care Options, LLC and Clinical Care Options 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

In this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include:

  • Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registrational trial today
  • Relevance of overall response rate vs progression-free survival for BTK inhibitor therapy
  • Approval of ibrutinib/venetoclax combination therapy for patients with CLL
  • Key differences between zanubrutinib and acalabrutinib in the treatment of patients with CLL
  • How to transition/overlap next therapy in patients with CLL with progression while receiving a BTK inhibitor

Faculty:
Farrukh T. Awan, MD
Associate Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Nicole Lamanna, MD
Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Link to the complete program, including downloadable slidesets and an on-demand webcast:
https://bit.ly/3EjvSKm

  continue reading

168集单集

所有剧集

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南